• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Recurrent Stroke after Silent Brain Infarction in Patients with Primary Brain Tumors (S51.007)
Conclusions:The short-term risk of recurrent ischemic stroke in patients with PBTs was substantial and the risk was comparable whether the stroke was silent or symptomatic.Study Supported by: Babak Navi was supported by grants from the NINDS (K23NS091395) and the Florence Gould Endowment for Discovery in Stroke. Hooman Kamel was supported by grants from the NINDS (K23NS082367) and the Michael Goldberg Stroke Research Fund.Disclosure: Dr. Parikh has nothing to disclose. Dr. Burch has nothing to disclose. Dr. Kamel has received personal compensation for activities with Genentech as a speaker. Dr. Kamel has received personal ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Parikh, N., Burch, J., Kamel, H., DeAngelis, L., Navi, B. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke Prevention and Translation Source Type: research

Recurrent stroke in childhood cancer survivors
Conclusion: Survivors of childhood cancer, particularly those previously treated with high-dose cranial radiation, have a high risk of recurrent stroke for decades after a first stroke. Although these strokes are mostly occurring in young adulthood, hypertension, an established atherosclerotic risk factor, independently predicts recurrent stroke in this population.
Source: Neurology - September 21, 2015 Category: Neurology Authors: Fullerton, H. J., Stratton, K., Mueller, S., Leisenring, W. W., Armstrong, G. T., Weathers, R. E., Stovall, M., Sklar, C. A., Goldsby, R. E., Robison, L. L., Krull, K. R. Tags: Childhood stroke, Stroke in young adults, All Cerebrovascular disease/Stroke, Primary brain tumor ARTICLE Source Type: research

Thrombolytic Outcomes for Acute Ischemic Stroke in Patients with Primary Brain Tumors in the United States (P4.220)
Conclusions: Thrombolytic therapy is an independent predictor of ICH in patients with primary brain tumors. Thrombolysis outcomes are less favorable in malignant brain tumors compared to benign tumors.Disclosure: Dr. Murthy has nothing to disclose. Dr. Moradiya has nothing to disclose. Dr. Shah has nothing to disclose. Dr. Shastri has nothing to disclose. Dr. Bershad has nothing to disclose. Dr. Suarez has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Murthy, S., Moradiya, Y., Shah, S., Shastri, A., Bershad, E., Suarez, J. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Thrombolysis Source Type: research

A Phase IIB Clinical Trial of Normobaric Oxygen Therapy (NBO) in Acute Ischemic Stroke (AIS) (S02.001)
CONCLUSIONS: NBO did not affect NIHSS or infarct growth in this trial. The observed imbalance in deaths remains unexplained, but appears unrelated to NBO. Further studies are warranted.Supported by: NIH-NINDS.Disclosure: Dr. Singhal has received personal compensation as an expert witness in medicolegal cases involving stroke in young adults. Dr. Singhal's wife is an employee of Vertex Pharmaceuticals, Inc. Dr. Singhal has received research support from Pfizer and Photothera, Inc. Dr. On Behalf of Partners SPOTRIAS Investigators has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Singhal, A., on Behalf of Partners SPOTRIAS Investigators, Tags: S02 Acute Stroke Therapy Source Type: research

Misdiagnosis in Young Patients with Ischemic Stroke (P7.122)
Conclusions It is essential to increase awareness that young patients with stroke may present to emergency department with minor symptoms of artery dissection mainly involving the posterior circulation and lacking cardiovascular risk factors.Disclosure: Dr. Leon has nothing to disclose. Dr. Pantiu has nothing to disclose. Dr. Quiroga has nothing to disclose. Dr. Bonardo has nothing to disclose. Dr. Uribe has nothing to disclose. Dr. Mazziotti has received research support from Shire Pharmaceuticals Group. Dr. Zinnerman has nothing to disclose. Dr. Martinez has nothing to disclose. Dr. Sotelo has nothing to disclose. Dr. Ju...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Leon, L., Pantiu, F., Quiroga, J., Bonardo, P., Uribe, C., Mazziotti, J., Zinnerman, A., Martinez, A., Sotelo, A., Jure, L., Nofal, P., Bendersky, E., Sposato, L. A., Riccio, P., Reisin, R., Fernandez Pardal, M. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke in Young Source Type: research

Cerebral perfusion in stroke-like migraine attacks after radiation therapy syndrome
We present 2 patients with recurrent attacks of SMART syndrome with increased cerebral blood volume in affected regions and abnormal vascular reactivity on transcranial Doppler ultrasound, suggesting a potential mechanism.
Source: Neurology - February 22, 2016 Category: Neurology Authors: Olsen, A. L., Miller, J. J., Bhattacharyya, S., Voinescu, P. E., Klein, J. P. Tags: MRI, All Clinical Neurology, All Cerebrovascular disease/Stroke, Radiation therapy-tumor CLINICAL/SCIENTIFIC NOTES Source Type: research

Stroke in Non-Bacterial Thrombotic Endocarditis: 31-Year Experience (P02.023)
CONCLUSIONS: This 31-year analysis shows that stroke is a frequent complication of NBTE, has severe clinical and radiological manifestations, and high associated mortality. Anticoagulation may not prevent stroke recurrence.Disclosure: Dr. Topcuoglu has nothing to disclose. Dr. Kursun has nothing to disclose. Dr. Karatas has nothing to disclose. Dr. Buonanno has nothing to disclose. Dr. Singhal has received personal compensation as an expert witness in medicolegal cases involving stroke in young adults. Dr. Singhal's wife is an employee of Vertex Pharmaceuticals, Inc. Dr. Singhal has received research support from Pfizer and Photothera, Inc.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Topcuoglu, M., Kursun, O., Karatas, H., Buonanno, F., Singhal, A. Tags: P02 Cerebrovascular Disease II Source Type: research

Stroke Subtypes and Risk Factors in Saudi Arabia (P1.124)
CONCLUSION: Non-cardioembolic disease was the overwhelming stroke mechanism in this middle-eastern cohort with only 4[percnt] of patients have cardioembolic stroke, in comparison to roughly 20[percnt] reported in Western cohorts. In part, these differences may be explained by deficient prolonged cardiac monitoring. However the high prevalence of atherothrombotic risk factors and overrepresentation of non-cardioembolic stroke suggests a need to optimize atherothrombotic stroke risk factor management within our populationDisclosure: Dr. Al Harbi has nothing to disclose. Dr. Shoamanesh has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Al Harbi, A., Shoamanesh, A. Tags: Cerebrovascular Disease: Epidemiology Source Type: research

A Case of Multiple Recurrent Ischemic Stroke in a Patient with Cholangiocarcinoma and Initiation of Anticoagulation Therapy for Secondary Stroke Prevention (P4.342)
CONCLUSIONS: Initiation of anticoagulation therapy and the optimal medications for secondary stroke prevention in cancer associated stroke remain controversial. Further randomized prospective studies are needed to establish treatment guidelines.Disclosure: Dr. Cheng has nothing to disclose. Dr. Then has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Cheng, J. Z., Then, R. Tags: Cerebrovascular Case Reports Source Type: research

Rates and Predictors of 1 year of Readmission with Seizures in Patients with Stroke and Stroke Subtypes: Analysis of a National Cohort of 557,033 Stroke Patients (P2.245)
Conclusions:Rate readmission of seizure after stroke within first year is low and there may be residual confounding by severity. Our findings do not support a need for routine prophylactic anti-epileptic drug use after stroke.Disclosure: Dr. Chaudhry has nothing to disclose. Dr. Chaudhry has nothing to disclose. Dr. Afzal has nothing to disclose. Dr. Gheith has nothing to disclose. Dr. Gu has nothing to disclose. Dr. Saeed has nothing to disclose. Dr. Safdar has nothing to disclose. Dr. Kassab has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Chaudhry, B., Chaudhry, S., Afzal, M.-R., Gheith, T., Gu, S., Saeed, A., Safdar, A., Kassab, M., Qureshi, A. Tags: Epilepsy and Clinical Neurophysiology: Clinical Epilepsy II Source Type: research

Fatal Embolic Stroke Due to Non-Atherothrombotic Mobile Thrombi in the Carotid Artery during Gastric Cancer Chemotherapy: An Autopsy Case Report (P01.255)
CONCLUSIONS: Multiple etiologies for ischemic stroke may exist in cancer patients. A mobile thrombus in the carotid artery should be considered as a possible mechanism for arteriogenic stroke in the clinical settings of malignancy with hypercoagulability. Doppler ultrasonography is the most practical tool to identify these conditions.Disclosure: Dr. Yamada has nothing to disclose. Dr. Yoneda has nothing to disclose. Dr. Arakawa has nothing to disclose. Dr. Adachi has nothing to disclose. Dr. Gotoh has nothing to disclose. Dr. Takagi has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Yamada, A., Yoneda, J., Arakawa, C., Adachi, T., Gotoh, J., Takagi, M. Tags: P01 Cerebrovascular Disease I Source Type: research

A Case of Perioperative Stroke Caused by Tumour Embolus. (P6.244)
CONCLUSIONS: Tumour embolism has previously been described with primary and secondary lung neoplasms, as well as cardiac tumours. Although rare, this should be considered as a potential cause of perioperative stroke in patients after cancer surgery.Study Supported by: Non-applicable.Disclosure: Dr. Hughes has nothing to disclose. Dr. Hunter has nothing to disclose. Dr. Campbell has nothing to disclose. Dr. Brady has nothing to disclose. Dr. Herron has nothing to disclose. Dr. Smyth has nothing to disclose. Dr. Rennie has nothing to disclose. Dr. Hunt has received personal compensation for activities with Eisai Inc., UCB Ph...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Hughes, S., Hunter, A., Campbell, J., Brady, A., Herron, B., Smyth, G., Rennie, I., Hunt, S. Tags: Cerebrovascular Disease and Interventional Neurology: Case Reports Source Type: research

Headache as a risk factor for neurovascular events in pediatric brain tumor patients
Conclusions: Severe recurrent headache appears to be a risk factor or predictor for subsequent cerebral ischemia in pediatric brain tumor survivors treated with radiation. This finding has clinical implications for both monitoring survivors and targeting a specific population for primary stroke prevention.
Source: Neurology - April 15, 2013 Category: Neurology Authors: Kranick, S. M., Campen, C. J., Kasner, S. E., Kessler, S. K., Zimmerman, R. A., Lustig, R. A., Phillips, P. C., Beslow, L. A., Ichord, R., Fisher, M. J. Tags: Childhood stroke, Pediatric headache, All Cerebrovascular disease/Stroke, Primary brain tumor, All Pediatric ARTICLE Source Type: research

Preconditioned M2 microglia by oxygen-glucose deprivation promote functional recovery in ischemic rats (P1.264)
Conclusions:Intravascular administration of M2 microglia preconditioned by OGD might be a novel therapeutic strategy against ischemic stroke.Disclosure: Dr. Kanazawa has nothing to disclose. Dr. Miura has nothing to disclose. Dr. Toriyabe has nothing to disclose. Dr. Koyama has nothing to disclose. Dr. Hatakeyama has nothing to disclose. Dr. Ishikawa has nothing to disclose. Dr. Nakajima has nothing to disclose. Dr. Onodera has nothing to disclose. Dr. Nishizawa has nothing to disclose. Dr. Shimohata has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Kanazawa, M., Miura, M., Toriyabe, M., Koyama, M., Hatakeyama, M., Ishikawa, M., Nakajima, T., Onodera, O., Nishizawa, M., Shimohata, T. Tags: Genetic Stroke Syndromes, Biomarkers, and Translational/Basic Research Source Type: research

Do severe headaches portend greater stroke risk following CRT for childhood brain tumor?
Children with brain tumors are more likely to survive, with survival rates improving consistently over several decades and well over 70% of patients now surviving 5 years from diagnosis.1 The vast majority of these children will become long-term survivors. As cure rates improve, a greater focus has been placed on enduring patient health after cancer treatment.
Source: Neurology - April 15, 2013 Category: Neurology Authors: Heyer, G. L., Mack, K. J. Tags: Childhood stroke, Pediatric headache, All Cerebrovascular disease/Stroke, Primary brain tumor, All Pediatric EDITORIALS Source Type: research

Pages: 1  2  3  4